(NASDAQ: IMUX) Immunic's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.6%.
Immunic's earnings in 2025 is -$103,047,000.On average, 11 Wall Street analysts forecast IMUX's earnings for 2025 to be -$76,152,259, with the lowest IMUX earnings forecast at -$78,978,950, and the highest IMUX earnings forecast at -$66,938,449. On average, 10 Wall Street analysts forecast IMUX's earnings for 2026 to be -$45,082,715, with the lowest IMUX earnings forecast at -$78,978,950, and the highest IMUX earnings forecast at -$22,986,411.
In 2027, IMUX is forecast to generate -$55,523,429 in earnings, with the lowest earnings forecast at -$62,475,886 and the highest earnings forecast at -$42,941,646.